118. Myelomeningocele
9 clinical trials,   15 drugs   (DrugBank: 7 drugs),   8 drug target genes,   11 drug target pathways

Searched query = "Myelomeningocele", "Myeloschisis", "Myelocele", "Myelocystocele", "Syringomyelocele"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04652908
(ClinicalTrials.gov)
February 202125/11/2020Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe TrialPhase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal MyelomeningoceleMyelomeningoceleBiological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrixDiana Lee FarmerCalifornia Institute for Regenerative Medicine (CIRM)Not yet recruiting19 Weeks25 WeeksAll35Phase 1;Phase 2NULL
2JPRN-UMIN000040088
2019/07/0107/04/2020Safety Assessment Clinical Test of Fetal Surgery for MyelomeningoceleSafety Assessment Clinical Test of Fetal Surgery for Myelomeningocele - Safety Assessment Clinical Test of Fetal Surgery for Myelomeningocele MyelomeningoceleMMC(Myelomeningocele) open fetal surgeryOSAKA UniversityDepartment of MedicineDivision of Obstetrics and GynecologyNULLRecruiting20years-oldNot applicableFemale15Not selectedJapan
3NCT04027374
(ClinicalTrials.gov)
July 1, 201916/7/2019Stress-associated Epigenetic Alterations in Newborns After Fetal SurgeryEpigenetic Alterations in Stress Regulation Genes Among Newborns After Fetal Surgery for Myelomeningocele Repair: An Exploratory StudyMeningomyeloceleProcedure: Fetal surgery for MMC repairUniversity Children's Hospital, ZurichUniversity of Zurich;Psychiatric University Hospital, ZurichRecruitingN/A3 MonthsAll90Switzerland
4NCT03936322
(ClinicalTrials.gov)
May 7, 20191/5/2019Minimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot StudyMinimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot StudySpina Bifida;Myelomeningocele;Neural Tube DefectsDevice: Minimally invasive fetoscopic repair of MMCMayo ClinicNULLEnrolling by invitation18 YearsN/AFemale15N/AUnited States
5NCT04362592
(ClinicalTrials.gov)
November 2, 201824/3/2020In-Utero Endoscopic Correction of Spina BifidaIn-Utero Endoscopic Correction of Spina Bifida: Laparotomy or PercutaneousNeural Tube Defects;Spina Bifida;MyelomeningoceleDevice: In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique;Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization TechniqueUniversity of Southern CaliforniaNULLRecruiting18 Years52 YearsFemale33N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02390895
(ClinicalTrials.gov)
May 17, 201715/2/2015Prenatal Endoscopic Repair of Fetal Spina BifidaPrenatal Endoscopic Repair of Fetal Spina BifidaMyelomeningoceleProcedure: endoscopic repair of myelomeningocele before 26 SAAssistance Publique - Hôpitaux de ParisNULLRecruiting18 YearsN/AFemale15N/AFrance
7NCT04468568
(ClinicalTrials.gov)
January 8, 20171/3/2020In Utero Repair of Myelomeningocele: Atosiban Versus TerbutalineAssessment of Maternal Blood Gas Changes When Using Atosiban and Terbutaline as Tocolytic Agents, During in Utero Repair of MyelomeningoceleMyelomeningocele;Terbutaline Adverse Reaction;Pregnancy; Malformation Central Nervous SystemDrug: Atosiban;Drug: TerbutalineUniversity of Sao Paulo General HospitalNULLRecruiting18 Years40 YearsFemale28N/ABrazil
8NCT04186338
(ClinicalTrials.gov)
December 1, 20162/12/2019Daily Physical Activity in MyelomeningoceleDaily Physical Activity in Children and Adolescents With Low Lumbar and Sacral Level MyelomeningocelePhysical ActivityDevice: Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)Marmara UniversityNULLCompleted6 Years16 YearsAll20NULL
9NCT00175123
(ClinicalTrials.gov)
May 20059/9/2005Effect of Botulinum Toxin in Neurogenic Bladders in Children With MyelomeningocelePhase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With MyelomeningoceleMyelomeningocele;Bladder, NeurogenicDrug: Botulinum A toxinUniversity of AarhusAarhus University HospitalActive, not recruiting2 Years16 YearsBoth30Phase 4Denmark